The linked editorial from JAMA Neurology cites IMPACT-AD, the course co-led by UCI MIND, and work by The 90+ Study investigators, Maria Corrada, ScM, ScD and Claudia Kawas, MD. The systematic review by Mooldijk et al1 summarizes multiple areas in which the field of dementia research can improve clinical studies. Our Editorial will focus on ethnic and racial diversity (primarily in the US) and on age differences noted in the systematic review between population-based cohorts and clinical cohorts. We also share new and ongoing efforts in this area from the National Institute on Aging (NIA) and the broader National Institutes of…
Read More
On June 28–29, 2021, the National Academies of Sciences, Engineering, and Medicine held a virtual workshop, “Behavioral and Social Research and Clinical Practice Implications of Biomarkers and Other Preclinical Diagnostics of Alzheimer's Disease (AD) and AD-Related Dementias” (AD/ADRD). UCI MIND Director Joshua Grill was an invited participant in this meeting, for which a brief report is now available.
Read More
Panel of experts from around the nation to give updates on what is the third leading cause of death in Orange County. UCI MIND and Alzheimer’s Orange County will host a free, virtual conference featuring experts discussing the latest developments in research around Alzheimer’s disease, which is Orange County’s third leading cause of death and afflicts more than 84,000 residents. The 32nd annual conference, “Alzheimer’s From All Angles,” will stream live on YouTube and Facebook on Sept. 10 from 8 a.m. to noon. One particularly timely topic will be what effect a viral disease like COVID-19 can have on brain…
Read More
Join Orange County Aging Services Collaborative on Sept 24th from anywhere! This conference is meant for older adults and those who support them. Family, friends, professionals, general public, community, and YOU! RSVP HERE: https://bit.ly/TSIGSept24
Read More
The National Institute on Aging has online health information in Spanish for older adults and caregivers on more than 60 topics related to healthy aging, caregiving, and Alzheimer’s disease and related dementias. https://www.nia.nih.gov/espanol
Read More
❓How will #aducanumab’s approval influence people’s willingness to join, and stay in, future Alzheimer’s disease #clinicaltrials? UCI MIND Director Joshua Grill, PhD was recently quoted by Alzforum discussing this topic. Read more about UCI MIND #InTheNews: https://www.alzforum.org/news/conference-coverage/aduhelm-approval-reverberates-through-research
Read More
Karen Zagorski of the Institute for Molecular Medicine in Huntington Beach presented data on a line of research conducted in collaboration with UCI MIND’s David Cribbs, Hayk Davtyan, and Matt Blurton-Jones.
Read More
NIA-supported scientists have developed a new mouse model that produces a form of the human beta-amyloid protein, a hallmark of Alzheimer’s disease. An important research tool, mouse models enable the exploration of genetic, environmental, and behavioral aspects of Alzheimer’s, as well as make it possible to test drug candidates before human studies. The new mouse model, which was reported in a recent article in Nature Communications, can be used by other scientists to advance Alzheimer’s research. Model Organism Development and Evaluation for Late-Onset Alzheimer’s Disease (MODEL-AD) MODEL-AD consortium Many factors, including gene changes, the aging process, and conditions in the…
Read More
UCI MIND at #AAIC María M. Corrada, ScM, ScD contributes: In The Life After 90 Study, a one-of-a-kind multiethnic cohort of individuals 90 and older, memory concerns appear to identify individuals with objective cognitive impairment but do not identify those whose cognition may decline faster. With additional enrollment and longer follow-up, we will continue to explore the utility of memory concerns in predicting future cognitive performance and potential ethnoracial differences in a segment of the population that is often excluded from research.
Read More
UCI MIND Director, Joshua Grill, PhD spoke today as part of a panel on the impact of drug approval on future clinical trials at the AAIC Annual Conference in Denver, CO. Dr. Grill presented on the ethical considerations needed for designing studies in the presence of an approved drug like Aduhelm. To learn more about this topic, read the recent paper he co-authored with Dr. Jason Karlawish in Neurology
Read More
